The lung tissues were, in a nutshell, fixed with 10% formalin for 24 h, embedded in paraffin, sectioned to 5-µm-thick, dewaxed with xylene, and dehydrated in ethanol at graded concentrations ... were ...

BMO Capital lowered the firm’s price target on Merck (MRK) to $96 from $105 and keeps a Market Perform rating on the shares after its ...

Merck is down 8.5% since the beginning of the year, and at $90.76 per share, it is trading 31.7% below its 52-week high of $132.96 from June 2024. Investors who bought $1,000 worth of Merck’s ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

Co. Inc. (NYSE:MRK), reducing the pharmaceutical giant's price target from $105.00 to $96.00, while keeping a Market Perform rating on the stock. Analysts at BMO Capital cited a decrease in confidence ...